2016/7/8 15:08


AsiaNet 65047(0842)

【トロント2016年7月7日PR Newswire=共同通信JBN】カナダのトロントに本社を置くLaborie Medical Technologies(以下LABORIE)はMedi-Tate Ltd.への投資を完了した。イスラエルのアキバに本社を置くMedi-Tateはイスラエルの医療機器会社で、良性前立腺肥大(BPH)を治療するための革新的ソリューションの研究、開発、製造、販売に集中している。






LABORIEは尿流動態学、胃腸学およびその他の骨盤底障害の分野で革新的医療技術と診断、治療消耗品を世界的に開発、製造、販売している有力会社である。LABORIEはAudax Private Equityのポートフォリオ企業である。

LABORIEの包括的な製品ラインに関する詳しい情報はwww.laborie.comまたは電話+1 905.612.1170へ。


Laborie Completes Strategic Investment In Medi-Tate Ltd.


TORONTO, July 7, 2016 /PRNewswire=KYODO JBN/ --

Laborie Medical Technologies ("LABORIE"), based in Toronto, Canada, has

completed an investment in Medi-Tate Ltd. Medi-Tate, headquartered in Akiva,

Israel, is an Israeli medical device company focused on research, development,

manufacture and sale of innovative solutions for the treatment of Benign

Prostatic Hyperplasia (BPH).

LABORIE's investment in Medi-Tate continues the company's focus on providing

innovative products to support Urology and Gastroenterology customers.

Medi-Tate has developed iTind, a minimally invasive procedure to treat the

symptoms of enlarged prostate in men whose primary other treatment options

would be pharmaceutical therapy or surgery. The iTind procedure uses a 5 day

implant to reshape the prostatic urethra and create new channels through which

urine can flow, without the complications associated with drugs and surgical

interventions. The iTind system for treatment of BPH is currently only

available for sale in the European Union and Canada. iTind is an

investigational device limited by federal law to investigational use only in

the United States.

"This is a very strategic investment for LABORIE," stated Brian Ellacott,

LABORIE President and CEO. "Medi-Tate has developed an innovative technology

for the treatment of BPH which overcomes the concerns of BPH sufferers - that

most of the available treatment options, whether pharmaceutical or surgical,

come with a risk of damaging the functionality of the prostate which in turn

can negatively affect sexual function."

Medi-Tate Founder and CEO, Ido Kilemnik stated, "We are very pleased to be

partnering with LABORIE. By combining our iTind technology with LABORIE's

Urology expertise and global footprint, we will be better able to quickly bring

the iTind solution to the over 500 million aging men impacted by BPH."


LABORIE is a leading global developer, manufacturer and marketer of innovative

medical technology and consumables for diagnosis and treatment in Urodynamics

and Gastroenterology as well as other pelvic floor disorders. LABORIE is a

portfolio company of Audax Private Equity.

For more information regarding LABORIE's comprehensive line of products, please

visit or call +1 905.612.1170